Express Pharma
Home  »  Pharma Life  »  Novartis wins two Prix Galien Foundation Awards

Novartis wins two Prix Galien Foundation Awards


Gleevec has been recognised as ‘Discovery of the Decade’ for Best Pharmaceutical Product, Cosentyx as Best Biotechnology Product

Novartis has received the 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx (secukinumab), as well as the Prix Galien Foundation ‘Discovery of the Decade’ Award for Best Pharmaceutical Product for the drug Gleevec (imatinib mesylate). The awards were presented at a ceremony in New York City. “We are honoured to receive these prestigious awards for Cosentyx and Gleevec, which not only have changed the practice of medicine for certain conditions, but also represent years of hard work by our scientists. These wins underscore our commitment to addressing the unmet medical needs of patients through science-based innovation,” said Joseph Jimenez, CEO, Novartis.

Cosentyx was the first fully human interleukin-17A (IL-17A) antagonist approved by the US Food and Drug Administration (FDA) in 2015 for the treatment of adults with moderate to severe plaque psoriasis. Cosentyx was also approved for the treatment of active ankylosing spondylitis and psoriatic arthritis in 2016.

The discovery of Gleevec marked the first time in the history of cancer treatment that scientists were able to identify a chromosomal abnormality and then develop a drug that would target that specific protein. Gleevec, a molecularly targeted treatment, became a therapy of choice for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) and KIT (CD117)-positive gastrointestinal stromal tumours (KIT+ GIST). By showing that certain diseases can share a drug-sensitive target with seemingly unrelated ailments, and that molecular targeting can be medically and commercially successful, Gleevec helped establish a new paradigm for drug development. The Prix Galien rewards excellence in scientific innovation that improves the state of human health.

EP News Bureau

Comments are closed.